Clinical Trial Update: Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and tolerability of long-term administration of OROS Hydromorphone HCl slow-release for cancer pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• OROS Hydromorphone HCl (Slow Release) (hydromorphone hydrochloride)

Snippet

Sponsor: Alza Corporation, DE, USA | Conditions: Analgesics, Opioid, Pain | Phase 3 | Status: COMPLETED